Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate

Biotech Targets Triple-Negative Breast Cancer and Lymphoma

 
• By Andrew McConaghie
  
Merck KGaA Darmstadt
Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip